VSAR
$1.65
Versartis
($.02)
(1.20%)
VSAR
Earnings Whisper ®
N/A
4th Quarter December 2017
Consensus:  ($0.88)
Revenue:  N/A
Tuesday
Mar 6
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when VSAR reports earnings?
Beat
Meet
Miss

Where is VSAR's stock price going from here?
Up
Flat
Down
Stock chart of VSAR
Analysts
Summary of analysts' recommendations for VSAR
Score
Grade
Pivots
Resistance
$1.80
$1.75
$1.70

$1.65

Support
$1.60
$1.55
$1.50
Tweet
Growth
Description
Versartis, Inc. operates as a biotechnology company. It develops therapeutic proteins for the treatment of metabolic diseases and endocrine disorders. The Company is developing VRS-317, a long-acting recombinant human growth hormone, which is in Phase 2a clinical trials for the treatment of growth hormone deficiency. Versartis, Inc. is headquartered in Redwood City, California.
Peers
CelgeneRegeneron PharmaceuticalsVertex PharmaceuticalsBioMarin PharmaceuticalJohnson & JohnsonZoetisEndo International plcEli LillyMylanPerrigo